晚期胆道癌免疫治疗:现状与未来方向
Immunotherapy in advanced biliary tract cancer: current status and future directions.
肿瘤细胞治疗研究
ALL SOURCES
把在研试验和前沿论文合在一起看,按时间倒序排列。本页条数 = 前沿论文 + 临床试验两块之和(导航里的「临床试验」板块只收在招的那部分,不另计入)。
Immunotherapy in advanced biliary tract cancer: current status and future directions.
Advances and challenges in immunotherapy for intrahepatic cholangiocarcinoma based on the tumour immune microenvironment.
通过整合机制、临床证据、分子亚型和转化局限性,本综述为 ICC 中生物标志物指导的精准免疫治疗提供了一个平衡的框架。对肝内胆管癌免疫治疗的临床证据和局限性进行了批判性评估,重点强调了对更广泛胆道癌试验的 ICC 特异性解读。将 ICC 肿瘤免疫微环境整合到涉及基质、髓系、淋巴系和代谢调节的功能性免疫轴中。分子亚型和免疫相关生物标志物为 ICC 中生物标志物指导的精准免疫治疗提供了框架。当前 ICC 免疫治疗试验仍受限于异质性设计、ICC
Cellular and molecular networks governing precursor exhausted CD8+ T cells in chronic liver disease: Implications for immunotherapy.
Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer.
本综述总结了过继性细胞疗法治疗胆道癌的最新进展,并讨论了促进临床转化的优化策略。
Advancing CAR-T cell therapy for cholangiocarcinoma: from bench to bedside and beyond.
Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies.
Advancing biliary tract malignancy treatment: emerging frontiers in cell-based therapies.
Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma.
Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins.
我们的结果显示,敲低六重抑制分子的 PTG-T16R-scFV-CAR-T 细胞在体外和体内均表现出对胆管癌的强大免疫力和长期疗效。该策略为胆管癌提供了一种有效且个性化的免疫细胞治疗。
Development of Engineered CAR T Cells Targeting Tumor-Associated Glycoforms of MUC1 for the Treatment of Intrahepatic Cholangiocarcinoma.
MEMBER ACCOUNT
登录成功会直接打开下一页。